Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Leisure Acquisition (LACQ) Competitors

LACQ vs. INDP, AEZS, KPRX, AYTU, MBIO, CDT, RDHL, VCNX, ENSC, and VINC

Should you be buying Leisure Acquisition stock or one of its competitors? The main competitors of Leisure Acquisition include Indaptus Therapeutics (INDP), Aeterna Zentaris (AEZS), Kiora Pharmaceuticals (KPRX), Aytu BioPharma (AYTU), Mustang Bio (MBIO), Conduit Pharmaceuticals (CDT), RedHill Biopharma (RDHL), Vaccinex (VCNX), Ensysce Biosciences (ENSC), and Vincerx Pharma (VINC).

Leisure Acquisition vs.

Indaptus Therapeutics (NASDAQ:INDP) and Leisure Acquisition (NASDAQ:LACQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.

Indaptus Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 717.31%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Indaptus Therapeutics is more favorable than Leisure Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Leisure Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$15.42M-$1.71-0.61
Leisure AcquisitionN/AN/A$4.31MN/AN/A

Leisure Acquisition's return on equity of 30.17% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -177.27% -141.06%
Leisure Acquisition N/A 30.17%6.14%

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 56.7% of Leisure Acquisition shares are held by institutional investors. 29.5% of Indaptus Therapeutics shares are held by insiders. Comparatively, 39.6% of Leisure Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Indaptus Therapeutics received 13 more outperform votes than Leisure Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
Indaptus TherapeuticsOutperform Votes
13
86.67%
Underperform Votes
2
13.33%
Leisure AcquisitionN/AN/A

In the previous week, Indaptus Therapeutics had 2 more articles in the media than Leisure Acquisition. MarketBeat recorded 2 mentions for Indaptus Therapeutics and 0 mentions for Leisure Acquisition. Indaptus Therapeutics' average media sentiment score of 0.54 beat Leisure Acquisition's score of -1.38 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Indaptus Therapeutics Positive
Leisure Acquisition Negative

Indaptus Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Leisure Acquisition has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500.

Summary

Indaptus Therapeutics beats Leisure Acquisition on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LACQ vs. The Competition

MetricLeisure AcquisitionPharmaceutical Preparations Industry SectorNASDAQ Exchange
Market Cap$3.41M$6.70B$1.98B$8.88B
Dividend YieldN/A8.07%15.23%4.07%
P/E RatioN/A11.3410.8317.98
Price / SalesN/A247.275,932.8467.54
Price / Cash20.0322.52123.7034.49
Price / Book-2.885.521.284.92
Net Income$4.31M$153.34M-$716.83M$225.84M

Leisure Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LACQ
Leisure Acquisition
N/A$0.55
+14.6%
N/A-45.6%$3.41MN/A0.00N/ANegative News
Gap Up
High Trading Volume
INDP
Indaptus Therapeutics
2.9818 of 5 stars
$1.02
+2.0%
$8.50
+733.3%
-51.0%$10.40MN/A0.006News Coverage
Gap Down
AEZS
Aeterna Zentaris
N/A$5.72
+5.9%
N/A-62.9%$10.26M$2.37M-0.3820Analyst Forecast
News Coverage
Gap Up
KPRX
Kiora Pharmaceuticals
2.733 of 5 stars
$3.39
+0.6%
$10.00
+195.0%
-32.9%$10.17MN/A0.0010
AYTU
Aytu BioPharma
0.8143 of 5 stars
$1.63
-0.3%
N/A-37.2%$9.99M$81M0.00160High Trading Volume
MBIO
Mustang Bio
1.4905 of 5 stars
$0.21
flat
$2.00
+875.1%
-88.0%$9.80MN/A-0.13100
CDT
Conduit Pharmaceuticals
N/A$0.09
-9.4%
N/A-95.1%$9.69MN/A0.003Gap Down
RDHL
RedHill Biopharma
0.5305 of 5 stars
$7.34
+8.3%
N/A-96.0%$9.40M$3.71M0.00210
VCNX
Vaccinex
N/A$3.55
-1.9%
N/A-72.1%$9.23M$570,000.00-0.0740Gap Up
ENSC
Ensysce Biosciences
0.0374 of 5 stars
$0.47
+9.3%
N/A-45.6%$9.20M$2.23M0.0010News Coverage
Gap Up
VINC
Vincerx Pharma
2.8493 of 5 stars
$0.27
+7.1%
$2.00
+640.7%
-65.1%$9.06MN/A0.0060

Related Companies and Tools


This page (NASDAQ:LACQ) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners